Evidence map›Paper›PMID 32037226›Full record

ArticleVaccine2020

Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.

Kathryn A Matthias, Alexandra Reveille, Kristie L Connolly, Ann E Jerse, Yamei S Gao, Margaret C Bash

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Protection againstFrontiers in immunology · 2025
    Article
  5. Article
  6. Review
  7. Characterisation and Immunogenicity ofFrontiers in immunology · 2024
    Article
  8. Review
  9. Outer-Membrane Vesicles ofMicroorganisms · 2023
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kathryn A MatthiasLaboratory of Bacterial Polysaccharides, Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave. Silver Spring, MD 20993, USA. Electronic address: kathryn.matthias@fda.hhs.gov.
Alexandra ReveilleLaboratory of Bacterial Polysaccharides, Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave. Silver Spring, MD 20993, USA. Electronic address: alexandra.reveille@fda.hhs.gov.
Kristie L ConnollyDepartment of Microbiology and Immunology, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD 20814, USA. Electronic address: kristie.connolly.ctr@usuhs.edu.
Ann E JerseDepartment of Microbiology and Immunology, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD 20814, USA. Electronic address: annjerse1@usuhs.edu.
Yamei S GaoCenter for Biologics Evaluation and Research Electron Microscopy Lab, Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave. Silver Spring, MD 20993, USA. Electronic address: yamei.gao@fda.hhs.gov.
Margaret C BashLaboratory of Bacterial Polysaccharides, Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave. Silver Spring, MD 20993, USA. Electronic address: margaret.bash@fda.hhs.gov.
Center for Biologics Evaluation and Research · USUniformed Services University of the Health Sciences · US

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

Detergent-extracted detoxified outer membrane vesicle (dOMV) vaccines are effective at preventing invasive serogroup B meningococcal (MenB) disease caused by the homologous Neisseria meningitidis strain from which they are produced, but offer limited protection from heterologous strains. Differences in vaccine efficacy are partially due to strain-specific variations in the antigenic sequence types and expression levels of outer membrane proteins (OMPs), including the immunodominant OMP PorA. In this study, dOMV vaccines deficient in major OMPs, including PorA, PorB, and RmpM were isolated and used to immunize rabbits and mice. Serum samples were obtained from each animal and tested for antibody responses against five MenB strains. Immunization with wild type dOMVs elicited antibodies to major antigens including PorA, PorB, RmpM, and lipooligosaccharide (LOS), and demonstrated limited bactericidal activity against heterologous strains. In contrast, OMP-deficient dOMV vaccines elicited broadly cross-reactive bactericidal antibodies, with PorA/PorB-dual deficient dOMVs inducing antibodies exhibiting the greatest cross-reactivity. Enhanced killing of heterologous strains correlated with binding to unique protein bands in immunoblots, suggestive of improved immunogenicity of antigens under-represented in the wild type vaccine.

Indexed as

Meningococcal InfectionsNeisseria meningitidis, Serogroup BAnimalsAntibodies, BacterialAntigens, BacterialBacterial Outer Membrane ProteinsCross ReactionsImmunogenicity, VaccineMeningococcal VaccinesMiceNeisseria meningitidisPorinsRabbitsSerogroupAntibodies, BacterialAntigens, BacterialBacterial Outer Membrane ProteinsMeningococcal VaccinesPorinsBactericidal antibodyNeisseria meningitidisOMVPorinserogroup BVaccine

Identifiers

PMID32037226
PMCPMC11656520
OpenAlexW3005112040

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.